Cite
HARVARD Citation
Bhattacharya, I. et al. (2018). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF‐06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects. Clinical pharmacology in drug development. 7 (5), pp. 484-497. [Online].